Please note: The information displayed on this page might be outdated.
Crescendo Biologics: Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific for PSMA-positive tumours. CB307’s unique format delivers highly potent tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. CB307 is in advanced pre-clinical development. Crescendo’s pipeline of T cell enhancing molecules is underpinned by its novel, patent-protected Humabody® platform, which generates fully human VH domains.
Backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group plc, Takeda, Quan Capital, Astellas Venture Management, EMBL Ventures, and Babraham Institute Enterprise.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Dermatology, Immuno-Oncology, Immunotherapy, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Meditrina Building 260
Babraham Research Campus
Cambridge, CB22 3AT
United Kingdom

Company Participants at European Biotech Investor Day 2020

  • Phil Bland-Ward, CDO